Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

• Status: Terminated
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals

Criteria

Inclusion Criteria:

• Males aged 18 or over

• Histologically proven adenocarcinoma of the prostate (all stages) in whom endocrine treatment was indicated (except neoadjuvant hormonal therapy)

• Has completed Study FE200486 CS07

• Has not met a withdrawal criteria at Visit 9 (day 28) in Study FE200486 CS07